The gut microbiome in oncology from a joke to one of the hallmarks of cancer

Joe Doupe Young Investigator Award

April 12, 2024

13:00 -

13:40 PDT

Room: Hyatt, Plaza Level (Second Floor), Plaza A/B
Open Session

All ICAM delegates are welcome to attend.

More Details...


The Joe Doupe Young Investigator award is given to a health scientist that demonstrates excellence in research training and has accomplished a significant and innovative study in the initial stages of their independent academic appointment.

Immune checkpoint blockers (ICB) have revolutionized the treatment of various cancers in both early and advanced stages. However current available biomarkers are neither sensitive nor specific at predicting outcome, and resistance to ICB is inevitable for most patients. Therefore, there is a world-wide unmet medical need for breakthrough concepts to predict outcome to ICB and to develop strategies to enhance long-term outcomes. Robust evidence has pointed to the various mechanisms by which intestinal bacteria act on distal tumors, and metagenomics profiling of patient stool prior to ICB revealed that baseline microbiome composition is associated with ICB clinical outcome and immune related toxicities. Recently positive clinical trials combining fecal microbiota transplantation with ICB opened novel therapeutic avenues in oncology.

At the end of this session, participants will:

  1. Discover the various mechanisms by which intestinal bacteria act on cancer immunotherapy response;
  2. Review the literature on the negative impact of antibiotics;
  3. Understand the various strategies to shift the microbiome composition.
Red topographic lines in circle.
Dr. Bertrand Routy
Associate Professor
CRCHUM, Université de Montréal

Attend ICAM 2024!

Don’t wait to reserve your spot at this leading international gathering dedicated to academic medicine.